In adults with sepsis, 20% albumin did not show a statistically significant mortality reduction compared to crystalloids alone across all sepsis cases , though a subgroup with septic shock showed a modest benefit that was not robust across statistical methods. Current sepsis guidelines recommend crystalloids as first-line with albumin use considered case-by-case.
Researchers conducted an updated systematic review and meta-analysis examining whether hyperoncotic albumin (20% concentration) reduces mortality in adults with sepsis or septic shock compared to crystalloid fluids alone. The analysis pooled data from eight randomized controlled trials involving 3,707 patients. This update was needed because sepsis management guidelines have shifted: the 2026 Surviving Sepsis Campaign guidelines now recommend crystalloids alone while permitting albumin use on a case-by-case basis, moving away from routine albumin administration.
The headline finding was null: across all patients with sepsis (both with and without shock), hyperoncotic albumin showed no robust association with reduced mortality. The overall risk ratio was 0.94 (meaning 6% relative lower mortality with albumin), but this result was fragile. It only reached statistical significance under one specific statistical correction method (Hartung-Knapp-Sidik-Jonkman correction), while remaining non-significant under standard, truncated, and fixed-effects approaches. The confidence intervals ranged from 0.87 to 1.03 depending on the method used, indicating the effect estimate crossed zero and therefore could not be considered definitively protective. This inconsistency across statistical approaches was attributed to low heterogeneity being incorrectly amplified as certainty, representing what the authors called a "low-heterogeneity artifact."
A pre-specified subgroup analysis examined whether results differed in the sicker population: patients with septic shock. Here, albumin showed a larger and more consistent effect (risk ratio 0.90, 95% confidence interval 0.82-0.99), reaching statistical significance at p = 0.03. This suggested a 10% relative mortality reduction in septic shock. However, this benefit was confined to septic shock; in sepsis without shock, albumin showed no benefit and even a trend toward harm (risk ratio 1.10), with a borderline interaction p-value of 0.08. The GRADE certainty of evidence for all findings was rated as low, meaning confidence in these estimates was modest and future research could change the conclusions.
If you or a family member experiences sepsis in a hospital setting, expect crystalloid fluids (normal saline or balanced crystalloids) as the standard initial fluid resuscitation. Albumin is expensive compared to crystalloids and this meta-analysis provides no compelling reason to use it routinely. The data do not support a blanket recommendation for 20% albumin in sepsis management.
That said, clinical judgment matters. The subgroup finding in septic shock suggests a possible signal worth investigating further, though it remains tentative. Your medical team might consider albumin on a case-by-case basis in severe septic shock if they believe individual clinical factors warrant it. This aligns with current guideline recommendations, which acknowledge that some patients might benefit even if routine use is not justified by evidence.
The key takeaway is that sepsis treatment should prioritize early recognition, antibiotics, source control, and fluid resuscitation with crystalloids. The evidence does not support albumin as a standard intervention, though research is ongoing to better characterize any benefit in the most critically ill subgroup.
| Parameter | Detail |
|---|---|
| Study Type | Systematic review and meta-analysis |
| Trials Included | 8 RCTs |
| Total Participants | 3,707 adults with sepsis or septic shock |
| Intervention | Hyperoncotic albumin (20%) |
| Comparator | Crystalloid fluids alone |
| Primary Outcome | All-cause mortality at longest follow-up |
| Main Finding | RR 0.94 (95% CI 0.87-1.03, p=0.17) overall; RR 0.90 (0.82-0.99, p=0.03) in septic shock subgroup |
| Certainty of Evidence | Low (GRADE) |
| Registration | PROSPERO (CRD420261334243) |
| Journal | Medical Sciences |
| PubMed ID | 42783423 |
| Search Period | Updated through March 2026 |
Hyperoncotic Albumin (20%) Versus Crystalloids for Mortality in Adults with Sepsis and Septic Shock: An Updated Systematic Review and Meta-Analysis. *Medical Sciences*. PubMed: https://pubmed.ncbi.nlm.nih.gov/42783423/
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.